Clalit Health Services, Jerusalem, Israel.
Hadassah University Hospital: Hadassah Medical Center, Jerusalem, Israel.
Eur J Pediatr. 2021 Sep;180(9):2943-2949. doi: 10.1007/s00431-021-04048-5. Epub 2021 Apr 9.
Approximately one in 100 babies has metatarsus adductus) MTA(. Although most deformities may resolve spontaneously, moderate and severe deformities might cause future discomfort and are therefore often treated. Common treatment alternatives include stretching, serial casting, and orthoses. Surgery is reserved for severe cases that are unresponsive to conservative management. The purpose of this study was to present our experience with a novel orthosis designed to correct and maintain correction of MTA in infants. Seventy-three children between the ages of 4 and 11.5 months with moderate to severe MTA were treated using the Universal Neonatal Foot Orthosis (UNFO). Treatment was started in cases of rigid deformity when the child was first seen in the clinic, or after the age of 5 months in children with moderate or severe but flexible deformity that failed to improve spontaneously. The orthosis was applied for 23 h daily. Weaning was started after a complete correction of the deformity was achieved. Follow-up was continued at least until walking age. Results were assessed utilizing the heel bisector line (HBL) as a measure of foot deformity before, during, and after treatment completion, and at the end of follow-up. Seventy-one patients (114 feet (were followed from the time of diagnosis to at least walking age. There were 102 severe (HBL at, or lateral to, the 4 toe) and 12 moderate MTA (HBL between 3 and 4 toes). Average age at the beginning of treatment was 6.58 months (range 4-11.5). Of the study population, 56 patients (98 feet) improved significantly by the end of the follow-up. In 11 children (11 feet), no change was noted, and in 3 children (3 feet), worsening of the deformity was observed at the end of follow-up. In one child who discontinued treatment after 6 weeks, there was no change in one foot and worsening in the other. Minor side effects were observed in 11 patients, all resolved uneventfully.Conclusion: UNFO is an effective treatment for moderate and severe MTA in children younger than10 months, with only infrequent minor side effects. What is Known: • Debate exists as to which patient warrants treatment since spontaneous improvement is the rule. However, some deformities persist to adulthood and may be esthetically unpleasing. • Treatment modalities available vary from benign neglect, special shoe ware that are either static or need special tools, and knowledge to adjust or casting by an orthopedic surgeon What is New: • This is a description of the results of treatment with a new orthotics which may be applied by pediatricians to treat this very common neonatal deformity. The orthotics provides an excellent, short duration solution, easy for the baby and caregiver with results comparable to those of more elaborate orthotics and casting • The use of digital pictures to assess forefoot adduction deformity severity instead of radiographs is a reliable measurement method.
大约每 100 个婴儿中就有 1 个患有内收性跖骨(MTA)。虽然大多数畸形可能会自发缓解,但中度和重度畸形可能会导致未来的不适,因此通常需要治疗。常见的治疗选择包括伸展、连续铸型和矫形器。手术仅适用于对保守治疗无反应的严重病例。本研究旨在介绍一种新型矫形器的使用经验,该矫形器用于纠正和维持婴儿 MTA 的矫正。73 名年龄在 4 至 11.5 个月之间的患有中重度 MTA 的儿童使用通用新生儿足部矫形器(UNFO)进行治疗。在患儿首次就诊时,如果存在僵硬性畸形,或者在 5 个月后出现中重度但可自行缓解的畸形时,开始使用矫形器。矫形器每天使用 23 小时。当畸形完全矫正后,开始逐渐减少使用时间。在治疗完成后以及随访结束时,使用足跟平分线(HBL)作为足部畸形的测量方法,对治疗前、治疗中和治疗完成后的结果进行评估。71 名患者(114 只脚)从确诊时至少随访到行走年龄。其中 102 例为重度(HBL 在第 4 趾或外侧),12 例为中度 MTA(HBL 在第 3 至 4 趾之间)。治疗开始时的平均年龄为 6.58 个月(范围为 4-11.5 个月)。研究人群中,56 名患者(98 只脚)在随访结束时明显改善。11 名儿童(11 只脚)无明显变化,3 名儿童(3 只脚)在随访结束时发现畸形加重。在 1 名治疗 6 周后停止治疗的儿童中,1 只脚无变化,另 1 只脚恶化。11 名患者出现轻微的副作用,均顺利解决。结论:UNFO 是治疗 10 个月以下儿童中重度 MTA 的有效方法,仅偶尔出现轻微副作用。已知情况:• 存在争议的是,哪些患者需要治疗,因为自发性改善是常见的。然而,一些畸形会持续到成年期,可能会影响美观。• 可用的治疗方法包括良性忽视、特殊的鞋子或需要特殊工具的静态鞋子,以及由矫形外科医生进行调整或铸型的知识。新情况:• 这是一种新型矫形器治疗结果的描述,儿科医生可以使用该矫形器治疗这种非常常见的新生儿畸形。矫形器提供了一种极好的、短期的解决方案,对婴儿和照顾者来说都很容易,其效果可与更复杂的矫形器和铸型相媲美。• 使用数字照片评估前足内收畸形严重程度而不是 X 光片是一种可靠的测量方法。